Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | HCAR3 | P49019 | 11/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10024452 | 0.90 | APEX1 (0.62) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL10024451 | 0.80 | PDE7A (0.40) | ALDH1A1LMNA | |
| SCHEMBL2001981 | 0.74 | APEX1 (0.72) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL3866808 | 0.73 | APEX1 (0.66) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL1025384 | 0.73 | APEX1 (0.66) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL1996412 | 0.73 | APEX1 (0.70) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL1025382 | 0.73 | APEX1 (0.69) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL15612193 | 0.73 | APEX1 (0.73) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL8215970 | 0.73 | APEX1 (0.65) | APEX1HCAR3TSHRCASP6ALDH1A1 | |
| SCHEMBL8422374 | 0.71 | APEX1 (0.71) | APEX1HCAR3TSHRCASP6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732382-B2 | Photodamage mitigation compounds and systems | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20150079603-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | PACIFIC BIOSCIENCES CALIFORNIA (US) | 2015-03-19 | — | — | US | disclosed |
| US-8834847-B2 | Photodamage mitigation compounds and systems | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120052488-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052488-A1 | PHOTODAMAGE MITIGATION COMPOUNDS AND SYSTEMS | CRY1, ERCC1, ERCC4 | APEX1 8/4885HCAR3 3592/4885TSHR 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.